Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from ADMA Biologics ( (ADMA) ) is now available.
Bryant E. Fong has resigned from ADMA Biologics’ Board of Directors to focus on his roles at Biomark Capital Fund and Stonepine Capital Management, with no disagreements reported. Young T. Kwon, PhD steps in as Chairman of the Audit Committee, alongside new committee members Steven A. Elms and Alison C. Finger, signaling a strategic reshuffle in the company’s governance.
Find detailed analytics on ADMA stock on TipRanks’ Stock Analysis page.